# Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men

> **NCT00363311** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 302 (actual)

## Conditions studied

- Neoplasms, Prostate

## Interventions

- **DRUG:** Dutasteride
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT00363311
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2010-03
- **Final completion:** 2010-07
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363311, "Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00363311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*